MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD)

Journal of Investigative Dermatology

Volumn 133, Issue 5, 2013, Pages 1286-1293

  Reuland, Steven N ^a   Smith, Shilo M ^a   Bemis, Lynne T ^b   Goldstein, Nathaniel B ^a   Almeida, Adam R ^a   Partyka, Katie A ^a   Marquez, Victor E ^c   Zhang, Qinghong ^a   Norris, David A ^a,d   Shellman, Yiqun G ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Affairs Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 26A; PROTEIN; PROTEIN BAG 4; SILENCER OF DEATH DOMAIN; SMAD1 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; ASSAY; BINDING SITE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84876530141     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.400     Document Type: Article

References (47)

1. Ades F, Metzger-Filho O (2012) Targeting the cellular signaling: BRAF inhibition and beyond for the treatment of metastatic malignant melanoma. Dermatol Res Pract 2012:259170
2. Alajez NM, Shi W, Hui AB et al. (2010) Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis 1:e85
3. Antoku K, Maser RS, Scully WJ Jr et al. (2001) Isolation of Bcl-2 binding proteins that exhibit homology with BAG-1 and suppressor of death domains protein. Biochem Biophys Res Commun 286:1003-10
4. Bell RE, Levy C (2011) The three M's: melanoma, microphthalmia-associated transcription factor and microRNA. Pigment Cell Melanoma Res 24:1088-106
5. Bonazzi VF, Stark MS, Hayward NK (2012) MicroRNA regulation of melanoma progression. Melanoma Res 22:101-13
6. Boni V, Zarate R, Villa JC et al. (2011) Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 11:429-36
7. Breitling R, Armengaud P, Amtmann A et al. (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573:83-92
8. Brockmann C, Leitner D, Labudde D et al. (2004) The solution structure of the SODD BAG domain reveals additional electrostatic interactions in the HSP70 complexes of SODD subfamily BAG domains. FEBS Lett 558:101-6
9. Buzaid AC (2004) Management of metastatic cutaneous melanoma. Oncology (Williston Park) 18:1443-50
10. Clague J, Lippman SM, Yang H et al. (2010) Genetic variation in microRNA genes and risk of oral premalignant lesions. Mol Carcinog 49:183-9
11. Cummins DL, Cummins JM, Pantle H et al. (2006) Cutaneous malignant melanoma. Mayo Clin Proc 81:500-7
12. Didiano D, Hobert O (2006) Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol 13:849-51
13. Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12:861-74
14. Flaherty KT (2010) Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Intern Med 153:587-91
15. Friedman RC, Farh KK, Burge CB et al. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92-105
16. Gogas HJ, Kirkwood JM, Sondak VK (2007) Chemotherapy for metastatic melanoma: time for a change?. Cancer 109:455-64
17. Howell PM Jr, Li X, Riker AI et al. (2010) MicroRNA in melanoma. Ochsner J 10:83-92
18. Ivanov VN, Bhoumik A, Ronai Z (2003) Death receptors and melanoma resistance to apoptosis. Oncogene 22:3152-61
19. Jiang Y, Woronicz JD, Liu W et al. (1999) Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 283:543-6
20. Kasinski AL, Slack FJ (2011) Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11:849-64
21. Kota J, Chivukula RR, O'Donnell KA et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-17
22. Kozomara A, Griffiths-Jones S (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39:D152-7
23. Kumar MS, Lu J, Mercer KL et al. (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39:673-7
24. Kumarswamy R, Mudduluru G, Ceppi P et al. (2012) MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is down-regulated in non-small cell lung cancer. Int J Cancer 130:2044-53
25. Leeper NJ, Raiesdana A, Kojima Y et al. (2011) MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol 226:1035-43
26. Lu J, He ML, Wang L et al. (2011) MiR-26a inhibits cell growth and tumori-genesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 71:225-33
27. Luzi E, Marini F, Sala SC et al. (2008) Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res 23:287-95
28. Madonna G, Dansky Ullman C, Gentilcore G et al. (2012) NF-kappaB as potential target in the treatment of melanoma. J Transl Med 10:53
29. Miki K, Eddy EM (2002) Tumor necrosis factor receptor 1 is an ATPase regulated by silencer of death domain. Mol Cell Biol 22:2536-43
30. Mitra D, Das PM, Huynh FC et al. (2011) Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem 286:40531-5
31. Mohamed JS, Lopez MA, Boriek AM (2010) Mechanical stretch up-regulates microRNA-26a and induces human airway smooth muscle hypertrophy by suppressing glycogen synthase kinase-3beta. J Biol Chem 285:29336-47
32. Mueller DW, Bosserhoff AK (2010) The evolving concept of 'melano-miRs'-microRNAs in melanomagenesis. Pigment Cell Melanoma Res 23:620-6
33. Nigam V, Sievers HH, Jensen BC et al. (2010) Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves. J Heart Valve Dis 19:459-65
34. Olaru AV, Ghiaur G, Yamanaka S et al. (2011) MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 54:2089-98
35. Ozawa F, Friess H, Zimmermann A et al. (2000) Enhanced expression of Silencer of death domains (SODD/BAG-4) in pancreatic cancer. Biochem Biophys Res Commun 271:409-13
36. Poser I, Bosserhoff AK (2004) Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol 19:173-88
37. Reuland SN, Goldstein NB, Partyka KA et al. (2011) The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. PLoS One 6:e24294
38. Reuland SN, Goldstein NB, Partyka KA et al. (2012) ABT-737 synergizes with Bortezomib to kill melanoma cells. Biology Open 1:92-100
39. Ruth MC, Xu Y, Maxwell IH et al. (2006) RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J Invest Dermatol 126:862-8
40. Sander S, Bullinger L, Klapproth K et al. (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112:4202-12
41. Sandhu S, Garzon R (2011) Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol 38:781-7
42. Shellman YG, Ribble D, Miller L et al. (2005) Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res 15:83-9
43. Tan J, Yang X, Zhuang L et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21:1050-63
44. Tao H, Hu Q, Fang J et al. (2007) Expression of SODD and P65 in ALL of children and its relationship with chemotherapeutic drugs. J Huazhong Univ Sci Technolog Med Sci 27:326-9
45. Wong CF, Tellam RL (2008) MicroRNA-26a targets the histone methyltransfer-ase enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 283:9836-43
46. Zhang B, Liu XX, He JR et al. (2011) Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 32:2-9
47. Zhu Y, Lu Y, Zhang Q et al. (2012) MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 40:4615-25